Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Antiandrogenic COC

Updated · Methodology

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Cyproterone acetate/ethinylestradiol is prescribed for acne and hirsutism. According to its own SmPC, it inhibits ovulation and acts as a hormonal contraceptive. It is taken by mouth, and the SmPC applies the warnings for combined oral contraceptives to it (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The same SmPC says that combined oral contraceptives reduce the effect of oral anticoagulants, probably because of an antagonistic effect on some clotting factors. However, they potentiate the effect of acenocoumarol. In women taking the product, laboratory tests can show raised prothrombin and factors VII, VIII, IX and X (cyproterone acetate/ethinylestradiol SmPC, AEMPS). So the documents disagree on the direction of the change. The acenocoumarol SmPC says oral contraceptives can reduce its effect, and the cyproterone acetate/ethinylestradiol SmPC says they can potentiate it.

Symptoms

The international normalised ratio (INR) can shift either way. According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The INR then falls below the target range, and protection against clots weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the cyproterone acetate/ethinylestradiol SmPC, the effect of acenocoumarol can increase instead (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The product itself raises the risk of venous thromboembolism, and epidemiological studies link hormonal contraceptives to a higher risk of arterial thromboembolism. Signs of thrombosis listed in its SmPC include unusual pain or swelling of one leg, sudden severe chest pain, sudden breathlessness, slurred speech and sudden weakness or numbness of one side or part of the body (cyproterone acetate/ethinylestradiol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the cyproterone acetate/ethinylestradiol summary of product characteristics (SmPC) rules out the product in current or past venous thrombosis (deep vein thrombosis, pulmonary embolism). If such a condition first appears during use, stop the product at once. So if acenocoumarol is prescribed for venous thrombosis, the product is contraindicated (cyproterone acetate/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the product in current or past arterial thrombosis, for example myocardial infarction, and in current or past stroke. It is also contraindicated in inherited or acquired predisposition to thrombosis, including antiphospholipid antibodies, in thrombogenic valvular disease and with one severe or several risk factors for thrombosis. The SmPC lists valvular heart disease and atrial fibrillation among factors that raise the risk of arterial thromboembolism and stroke (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). If thrombosis is suspected or confirmed, stop the product and choose a suitable contraceptive method, because coumarins are teratogenic (cyproterone acetate/ethinylestradiol SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). The cyproterone acetate/ethinylestradiol SmPC, by contrast, says that combined oral contraceptives potentiate the effect of acenocoumarol, so the international normalised ratio (INR) may shift either way (cyproterone acetate/ethinylestradiol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol